In one of the most surprising news today, Dynavax Technologies Corporation (NASDAQ:DVAX) has announced that the first clinical data of their HEPLISAV has shown increase in the protection rate for chronic kidney disease patients. The data will be presented publicly in a poster session on Saturday, October 31, 2009 at the Annual Meeting of the Infectious Disease Society of America (IDSA) in Philadelphia, Pennsylvania.

Dynavax Technologies Corporation is a biopharmaceutical company that discovers and develops product candidates like Toll-like Receptor also known as TLR. HEPLISAV is a Phase 3 adult hepatitis B vaccine that provides increased and rapid protection to the patients with fewer doses compare to the current licensed vaccines available in the market. During the Phase 3 trial of HEPLISAV around 2500 individuals were vaccinated with